TARO - Taro Pharmaceutical Industries

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M
• Taro Pharmaceutical Q2 2023 Earnings Preview
• Intellipharmaceutics inks license deal with Taro for depression tablets desvenlafaxine
• Hot Stocks: REV surges 30%; TRQ plunges; HRB sets 52-week high; TARO hits 52-week low
• Taro Pharmaceutical hits 52-week low; down 28% YTD
• Taro recalls certain lots of bone disorder drug in Canada on particulate matter concerns
• Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M
• Taro Pharmaceutical GAAP EPS of $0.73, revenue of $143.26M
• Taro Pharmaceutical Q1 2022 Earnings Preview
• Taro Pharmaceutical to acquire Alchemee from Galderma
• Taro Pharmaceutical GAAP EPS of $0.70 misses by $0.21, revenue of $138.98M misses by $3.24M
• Taro Pharmaceutical Q3 2022 Earnings Preview
• Taro Pharmaceutical names new finance chief
• Taro Pharmaceutical EPS misses by $0.36, misses on revenue
• Taro Pharmaceutical to pay $213M over price fixing allegtions
• Taro Pharmaceutical EPS beats by $0.25, beats on revenue
• Taro Pharma's CFO Daphne Huang resigns
• Taro Pharmaceutical EPS misses by $0.11, beats on revenue
• Taro Pharmaceutical EPS misses by $0.15, misses on revenue
• Taro Pharmaceutical EPS beats by $0.41, beats on revenue